Aurora Cannabis Achieves Australia';s TGA GMP Certification, Setting Global Standard for Quality and Compliance

Rhea-AI Summary

Aurora Cannabis Inc. achieves Good Manufacturing Practice certification from Australia's Therapeutic Goods Administration for its Canadian production facilities, enhancing its position in the Australian medical cannabis market.

Positive

• Aurora Cannabis Inc. receives GMP certification from Australia's TGA for its Canadian facilities.
• The certification allows Aurora to deliver high-quality cannabis products to Australia in compliance with TGA regulations.
• Aurora can now expand its product offerings in Australia, including dried flower, resin cartridges, pastilles, and oils.
• The certification reaffirms Aurora's commitment to quality, compliance, and global standards.
• The Australian medical cannabis market is rapidly growing and estimated to be worth $400 million AUD.
• Aurora's partnership with MedReleaf Australia strengthens its position as a key player in the Australian market.

Negative

• None.

Milestone Achievement Signals Company's Commitment to Solidifying its Leadership in the Australian Market

                                                                                           NASDAQ | TSX: ACB

EDMONTON, AB, March 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – The Canadian based leading global medical cannabis company has received Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration (TGA) for its Canadian production facilities, River and Ridge. The TGA is responsible for regulating the supply, import, export, manufacturing and advertising of therapeutic goods in Australia.  Obtaining TGA's GMP certification enables the company to deliver top-tier cannabis products to Australia while confirming Aurora's dedication to exporting products fully compliant with TGA regulations and the stipulations of TGO 93 (Standard for Medical Cannabis). The license grants approval for Aurora to broaden its product range offerings in the country, comprising dried flower, resin cartridges, pastilles and oils.

"I'm proud to announce Aurora has obtained TGA GMP certification for our world class Canadian production facilities," said Gorana Lakic, Vice President, Quality at Aurora. "This achievement adds to the number of global certifications Aurora has received and solidifies our dedication to quality and compliance. With this significant achievement, we reaffirm our commitment to maintaining the highest standards and manufacturing practices to deliver premium medical cannabis products to our valued patients."

This landmark certification, granted on March 15, 2024, strengthens Aurora's dedication to supporting the continued growth and development of the Australian medical cannabis market, which is rapidly expanding and estimated to be worth $400 million AUD, making it the largest medical market in the world outside of North America.¹ As the long-standing exclusive supplier to MedReleaf Australia, and recently announced parent company, Aurora will continue to introduce innovative and differentiated products to the market.

MedReleaf Australia and Aurora remain dedicated to ensuring Australian patients can access a dependable and consistent supply of premium-quality products and providing doctors expanded options for patient care.

For further information about medical cannabis products, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.

_________________________________

1 The Pennington Institute, "Cannabis in Australia 2023."  (Estimated revenue of AUD$210m for January to June 2023 has been annualized)

About Aurora Cannabis 

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn. 

Aurora's Common Shares trade on the NASDAQ and TSX under the symbol "ACB" and is a constituent of the S&P/TSX Composite Index. 

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the Company's continued dedication to the growth and development of the Australian medical cannabis market and to exporting products fully compliant with TGA regulations and the stipulations of TGO 93, the Company's continued expansion of the Company's product range offerings in Australia, and expectations for the size of the Australian medical cannabis market.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 14, 2023 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-achieves-australias-tga-gmp-certification-setting-global-standard-for-quality-and-compliance-302093989.html

SOURCE Aurora Cannabis Inc.

FAQ

What certification did Aurora Cannabis Inc. receive from Australia's TGA?

Aurora Cannabis Inc. received Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration for its Canadian production facilities.

What products can Aurora now offer in Australia after obtaining the certification?

Aurora can now offer dried flower, resin cartridges, pastilles, and oils in Australia.

How does the certification benefit Aurora?

The certification allows Aurora to deliver top-tier cannabis products to Australia in compliance with TGA regulations, reaffirming its commitment to quality and compliance.

What is the estimated worth of the Australian medical cannabis market?

The Australian medical cannabis market is estimated to be worth $400 million AUD, making it one of the largest in the world outside of North America.

Who is Aurora's exclusive supplier in Australia?

Aurora is the exclusive supplier to MedReleaf Australia in the Australian market.

What is the significance of the partnership between Aurora and MedReleaf Australia?

The partnership ensures Australian patients have access to premium-quality medical cannabis products and provides doctors with expanded options for patient care.